On November 15, 2020, after 4 months in substantial-scale Period 3 clinical screening, Moderna gained resounding evidence that its new class of medications based mostly on messenger RNA encased in lipid nanoparticles could be securely deployed as a remarkably powerful vaccine to fight the COVID-19 pandemic.